🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At #GUtrends25 we compared EV, SG, Erda(FGFR +ves), taxane +/- ramucirumab (VEGFR mAB) in pretreated urothelial cancer. The control arms performed similarly. EV & Erda (FGFR+) look quite similar, but SG slightly less activity & ⬆️ tox. Ram got PFS but no OS, halting VEGF in UC.

Review Nature Rev Immunol Lorenzo Galluzzi Cell Stress & Immunity (CSI) Lab The diversity of CD8+ T cell dysfunction in cancer and viral infection nature.com/articles/s4157…

Review: Diverse potential of CAR-engineered cell therapy: Beyond cancer onlinelibrary.wiley.com/doi/10.1002/ct…

細胞間でミトコンドリアがやり取りされていることがいかなる生物学的意義があるかをまとめて紹介している記事。Nature。 nature.com/articles/d4158…

Our team's review on 'Personalized treatment for mRCC' is now published! Exploring recent advances in targeted therapies, immunotherapy, and biomarker-guided approaches. #KidneyCancer #PrecisionMedicin tandfonline.com/doi/epdf/10.10…

オミクス技術の発展で生物データは急増していますが、その解析は追いついていません。ゲノミクス、トランスクリプトミクス等の多様なオミクスデータを統合し事前学習するマルチモーダル基盤モデルに向けたNatureの展望です。 nature.com/articles/s4158…

Online Now: Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts dlvr.it/TKMty0

BOND-003: The final analysis of Intravesical Cretostimogene Grenadenorepvec (n=112). for High-Risk BCG unresponsive NMIBC with CIS. CR=75% & 12 months DFS= 50% (of ITT population). This looks in line with other adenoviral gene therapies - INFa (adstiladein) #AUA25

Congratulations to Dr. Lin for completing the fellowship program at the Cancer Institute Hospital of JFCR. You accomplished great things in the program. We wish you boundless success in the future.

Updated SUNRISE1 -TAR-200 has a CR rate 83% (50% at 12 months) in BCG unresponsive NMIBC. Impressive. Other single arm data for Il-15/ adenovival vectors are within the same range. Cross trial comparisons of modest sized single arm trials is tricky. #AUA25 time for randomisation?

In Situ Detection of Individual Classic MHC-I Gene Products in Cancer: brnw.ch/21wSlNc

POTOMAC trial- Durvalumab + BCG shows positive results for DFS in high-risk NMIBC vs BCG alone. sasanlimab (CREST) also had an EFS advantage here: HR 0.68. Consistent results in early disease is compelling. IO tox is relevant in risk/benefit ratio. astrazeneca.com/media-centre/p…

がん研有明病院総合腫瘍科のページをリニューアルしました。 泌尿器がん、頭頸部がん、肉腫、婦人科がん、原発不明がん、希少がんを、それぞれの分野のスペシャリストの腫瘍内科医が診療にあたっています。 jfcr.or.jp/hospital/depar…

Integrity: 真摯な態度で向き合おう Discovery: 新しいものを見つけに行こう Devotion: 思いやりの心で人のためになることをしよう がん研有明病院総合腫瘍科は、このようなコアバリューの元に、チーム一丸で取り組んで行きます。 jfcr.or.jp/hospital/depar…

Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. ja.ma/4jePW1F

ジャパンキャンサーフォーラム(japancancerforum.jp) で原発不明がんについてお話しさせていただきます。オンデマンド配信です. japancancerforum.jp/programs/2025/…

Yuji Miura Great to connect and collaborate across borders 🌍 Science speaks one language: progress. #ASCO25 #oncology #GlobalOncology OncoAlert ASCO

Meet the Legend@ASCO. Dr. Einhorn. 歴史と経験を感じる正にレジェンドによる講演‼️医学生に戻った気分でした。#ASCO25 #DrEinhorn #GermCellTumor